

High *PTEN* gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function

Breast Cancer Research and Treatment

Authors:

Synnøve Yndestad^{1,2}, Eilin Austreid¹, Stian Knappskog^{1,2}, Ranjan Chrisanthar³, Peer Kåre Lilleng^{4,5}, Per Eystein Lønning^{1,2}, Hans Petter Eikesdal^{1,2*}

Author details:

¹Section of Oncology, Department of Clinical Science, University of Bergen, Bergen, Norway.

²Department of Oncology, Haukeland University Hospital, Bergen, Norway.

³Section of Molecular Pathology, Department of Pathology, Oslo University Hospital, Oslo, Norway.


⁴Department of Pathology, Haukeland University Hospital, Bergen, Norway.

⁵Laboratory of Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

***Correspondence:** hans.eikesdal@k2.uib.no

Online Resource 5

a-b Forest plot for the association between tumor protein staining by immunohistochemistry (IHC) and recurrence-free (**a**) or disease-free survival (**b**) in patients with locally advanced breast cancer. Results are presented as individual hazard ratios (HRs) with corresponding 95% confidence intervals (CIs), based on tissue microarray staining and survival data from Study 3 (epirubicin/paclitaxel trial). $HR > 1$ indicates that the survival of patients with protein staining is shorter than that of patients without protein staining in the tumors, while $HR < 1$ indicates the opposite. Number of samples analyzed per protein vary due to technical issues during tissue microarray staining. *One case censored before the earliest event in a stratum. RFS: recurrence-free survival, DSS: disease-specific survival, wt: wildtype, mut: mutated, ER: estrogen receptor, pAkt: phosphorylated Akt (Ser 473), pS6K (Ser 371): phosphorylated S6 kinase (Ser 371), pS6K (Thr 389): phosphorylated S6 kinase (Thr 389), p4EBP1: phosphorylated 4EBP1 (Thr 70), c: cytoplasmic staining, n: nuclear staining

a**b**